PHAXIAM Therapeutics S.A.
PHAXIAM Therapeutics S.A., a clinical-stage biopharmaceutical company, focuses on developing bacteriophage-based therapies for severe resistance infections in France. The company develops and commercializes red cell-based therapies for cancers and orphan diseases. It develops anti-infectious therapies based on the use of bacteriophages (phages) to treat infections caused by Escherichia coli (E.co… Read more
PHAXIAM Therapeutics S.A. (PHXM) - Total Liabilities
Latest total liabilities as of June 2024: €23.66 Million EUR
Based on the latest financial reports, PHAXIAM Therapeutics S.A. (PHXM) has total liabilities worth €23.66 Million EUR as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
PHAXIAM Therapeutics S.A. - Total Liabilities Trend (2010–2023)
This chart illustrates how PHAXIAM Therapeutics S.A.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
PHAXIAM Therapeutics S.A. Competitors by Total Liabilities
The table below lists competitors of PHAXIAM Therapeutics S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
DELPHI WORLD MONEY LIMITED
NSE:DELPHIFX
|
India | ₹5.86 Billion |
|
UTime Limited
NASDAQ:WTO
|
USA | $343.89 Million |
|
GGX Gold Corp
PINK:GGXXF
|
USA | $1.59 Million |
|
Greenwing Resources Ltd
PINK:BSSMF
|
USA | $4.50 Million |
|
BRUNSWICK
BE:BWI
|
Germany | €3.99 Billion |
Liability Composition Analysis (2010–2023)
This chart breaks down PHAXIAM Therapeutics S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.38 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.09 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.60 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PHAXIAM Therapeutics S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PHAXIAM Therapeutics S.A. (2010–2023)
The table below shows the annual total liabilities of PHAXIAM Therapeutics S.A. from 2010 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | €25.70 Million | +15.10% |
| 2022-12-31 | €22.32 Million | -49.17% |
| 2021-12-31 | €43.92 Million | -18.45% |
| 2020-12-31 | €53.86 Million | +63.29% |
| 2019-12-31 | €32.99 Million | +48.33% |
| 2018-12-31 | €22.24 Million | +60.66% |
| 2017-12-31 | €13.84 Million | +48.38% |
| 2016-12-31 | €9.33 Million | +58.87% |
| 2015-12-31 | €5.87 Million | +22.79% |
| 2014-12-31 | €4.78 Million | +9.63% |
| 2013-12-31 | €4.36 Million | -69.22% |
| 2012-12-31 | €14.17 Million | +106.96% |
| 2011-12-31 | €6.85 Million | +165.59% |
| 2010-12-31 | €2.58 Million | -- |